The authors aimed to investigate whether the combination would exhibit antidepressant activity in these patients.
They conducted a multicentre, randomised, double-blind, placebo-controlled, two-stage sequential parallel comparison design study in adults with major depression who had an inadequate response to one or two courses of antidepressant treatment.
The authors, led by Maurizio Fava, MD, of the Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, reported that: “The buprenorphine/samidorphan combination is a novel and promising candidate for treatment of major depressive disorder in patients who have an inadequate response to standard antidepressants.”
Read the abstract and access the pay-per-view on the website of the American Journal of Psychiatry.
Leave a Reply